Ovid Therapeutics (OVID) Stock Rating Reaffirmed by Cowen
Cowen restated their buy rating on shares of Ovid Therapeutics (NASDAQ:OVID) in a research report sent to investors on Sunday morning, AnalystRatings.com reports.
OVID has been the subject of a number of other research reports. Zacks Investment Research cut Ovid Therapeutics from a buy rating to a hold rating in a report on Saturday, April 6th. Piper Jaffray Companies dropped their target price on Ovid Therapeutics to $14.00 and set an overweight rating for the company in a report on Sunday, March 10th. JMP Securities dropped their target price on Ovid Therapeutics from $26.00 to $11.00 and set an outperform rating for the company in a report on Friday, March 8th. ValuEngine lowered Ovid Therapeutics from a hold rating to a sell rating in a research note on Wednesday, May 1st. Finally, LADENBURG THALM/SH SH set a $27.00 price target on Ovid Therapeutics and gave the stock a buy rating in a research note on Friday, March 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $12.85.
Shares of Ovid Therapeutics stock opened at $1.74 on Friday. The company has a market capitalization of $64.23 million, a PE ratio of -0.82 and a beta of 2.10. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.78. Ovid Therapeutics has a one year low of $1.56 and a one year high of $11.45.
In other Ovid Therapeutics news, CEO Jeremy M. Levin purchased 75,000 shares of the firm’s stock in a transaction that occurred on Friday, February 22nd. The stock was purchased at an average cost of $2.00 per share, with a total value of $150,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 43.90% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the stock. Morgan Stanley lifted its stake in shares of Ovid Therapeutics by 225.6% during the 1st quarter. Morgan Stanley now owns 125,906 shares of the company’s stock worth $224,000 after acquiring an additional 87,238 shares during the last quarter. AWH Capital L.P. bought a new stake in shares of Ovid Therapeutics during the 1st quarter worth approximately $407,000. Oxford Asset Management LLP lifted its stake in shares of Ovid Therapeutics by 160.2% during the 1st quarter. Oxford Asset Management LLP now owns 61,066 shares of the company’s stock worth $108,000 after acquiring an additional 37,599 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Ovid Therapeutics by 72.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 100,598 shares of the company’s stock valued at $179,000 after purchasing an additional 42,127 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Ovid Therapeutics by 559.2% during the 1st quarter. Renaissance Technologies LLC now owns 363,217 shares of the company’s stock valued at $643,000 after purchasing an additional 308,117 shares in the last quarter. 17.55% of the stock is owned by hedge funds and other institutional investors.
About Ovid Therapeutics
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Recommended Story: Forex
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.